Methods for treating central or peripheral nervous system damage
A composition comprising a novel Ca 2+ -activated, [ATP] i -sensitive nonspecific cation (NC Ca-ATP ) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca] i . The NC Ca-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NC Ca-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NC Ca-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.
1. A method of treating a subject for central or peripheral nervous system damage, said damage comprising expression of a NC Ca-ATP channel in neural cells, comprising administering a pharmaceutical composition comprising a compound effective to inhibit the activity of a NC Ca-ATP channel in a neural cell and a pharmaceutically acceptable carrier to the subject, wherein the compound is a sulfonylurea receptor 1 (SUR1) antagonist selected from a sulfonylurea compound, a benzamido derivative, LY397364, LY389382, and a combination thereof, wherein said administration of the SUR1 antagonist inhibits the NC Ca-ATP channel in neural cells expressing the channel, thereby treating said central or peripheral nervous system damage.
2. The method of claim 1 , wherein the central or peripheral nervous system damage comprises traumatic brain injury, cerebral ischemia, hypoxia, or bleeding in the brain.
3. The method of claim 1 , wherein the subject has suffered a stroke.
4. The method of claim 1 , wherein said composition is administered intravenously, subcutaneously, orally, intramuscularly, intracutaneously, intragastricly, or directly into the brain.
5. The method of claim 1 , wherein the SUR1 antagonist is a glibenclamide, a tolbutamide, a repaglinide, a nateglinide, a meglitinide, LY397364, LY389382, a gliclazide, a glimepiride, and combinations thereof.
6. The method of claim 1 , wherein the SUR1 antagonist is a glibenclamide.
7. The method of claim 6 , wherein the glibenclamide is administered to the subject at a dose between about 0.5 milligrams and 150 milligrams.
8. The method of claim 6 , wherein the glibenclamide is administered to the subject in a dose of 1 mg to 1000 mg per day.
9. The method of claim 6 , wherein the glibenclamide is administered to the subject in a dose of 1 mg to 100 mg per day.
10. The method of claim 6 , wherein the glibenclamide is administered to the subject in a dose of 1 mg to 10 mg per day in a single dose or multiple doses.
11. The method of claim 6 , wherein the glibenclamide is administered to the subject in a dose of 1 mg to 5 mg per day in a single dose.
12. The method of claim 6 , wherein the glibenclamide is administered in combination with one or more further active agents that affect the subject's central or peripheral nervous system.
13. The method of claim 5 , wherein the SUR1 antagonist is administered in the form of capsules, tablets, pills, powders, gelcaps, or granules to the subject.
14. The method according to claim 1 , further comprising administering MgADP to the subject.
15. The method of claim 1 , wherein the SUR1 antagonist is administered to the subject in a dose at a substantially constant level for a given period of time.
16. The method of claim 15 , wherein the given period of time is about six or more hours.
17. The method of claim 15 , wherein the given period of time is about twelve or more hours.
18. The method of claim 15 , wherein the given period of time is about twenty-four or more hours.